Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117670 | 0.89 | GRM2 (0.33) | HTR2AHTR2CHTR2BGRM2 | |
| SCHEMBL20117614 | 0.87 | FGFR2 (0.32) | HTR2AHTR2CHTR2BGRM2 | |
| SCHEMBL20111359 | 0.86 | HTR2A (0.31) | HTR2AHTR2C | |
| SCHEMBL20111705 | 0.84 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL20111716 | 0.82 | SCN9A (0.36) | HTR2AHTR2CHTR2BSLC6A9 | |
| SCHEMBL20111269 | 0.81 | HTR2A (0.33) | HTR2AHTR2CHTR2BSLC6A9 | |
| SCHEMBL20111546 | 0.78 | PDE4A (0.33) | HTR2AHTR2CHTR2BSLC6A9 | |
| SCHEMBL20117659 | 0.76 | FGFR2 (0.30) | — | |
| SCHEMBL20111370 | 0.75 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL20111355 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | HTR2A 791/4885HTR2C 134/4885HTR2B 651/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | HTR2A 791/4885HTR2C 134/4885HTR2B 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.